Eric Ries is a Co-Founder of Long-Term Stock Exchange, where he serves as President, Chief Executive Officer & Board Member. He created the Lean Startup methodology and wrote the New York Times bestseller The Lean Startup, which has sold over one million copies and has been translated into more than 30 languages. Ries founded IMVU and served as an Entrepreneur-in-Residence at Harvard Business School, IDEO and Pivotal. He was named by Fortune to its 2018 "40 Under 40" ranking of the most influential young people in the business. He is also an angel investor.
Yi Shi
Investing in Other • Education • BioTec...
Shanghai China, China
Previous Investments
• Hangzhou Just Biotherapeutics (Just China):
$400000000 (Later stage VC)
Dr. David Lowe is a Co-Founder of Aeglea BioTherapeutics Holdings. He also served as Chief Executive Officer at Aeglea BioTherapeutics. He is a Board Member at Shattuck Labs. He is a Board Member at MaRS Innovation.. Previously, he srved as managing director at Skyline Ventures. Dr. Lowe joined Skyline Ventures in 2002 and became a partner at Skyline in 2003. Prior to joining Skyline, Dr. Lowe was employed at Genentech, a biotherapeutics company, from 1985 to 2001, where he led drug discovery activities in biologics and small molecule therapeutics. Dr. Lowe held various positions while at Genentech including Director of Cardiovascular Research. Dr. Lowe currently serves on the Boards of Directors of Applied Genetics Technologies Corporation, Proteon Therapeutics, and ARCA Discovery. Dr. Lowe holds B.S. and Ph.D. degrees in biochemistry from the University of Toronto, Canada
Roxanne Varza
Investing in Software (Web Marketplace Saas..) &b...
Roxanne Varza is currently Director of STATION F, the biggest startup campus in the world with more than 1,000 startups, located in Paris. She is also an angel investor (companies include Claap, Folk, Resilience.care, Moka.care, Colette and more) and scout for Sequoia Capital (and was previously a scout at Atomico).Before joining STATION F, sheled Microsoft Ventures Paris and was Editor of TechCrunch France. She also worked for several London-based startups and cofounded StarHer (now part of SISTA), Tech.eu and Failcon France. She has also been a member of the French Government's Conseil National du Numérique (CNNum) and the European Commission's European Innovation Council (EIC).Roxanne is trilingual and holds degrees from UCLA, Sciences Po Paris and the London School of Economics.
Mason Ng
Investing in Software (Web Marketplace Saas..) &b...
Valley California , S..., U.S.A.
Mason Ng
Valley California - San Mateo California - California - U.S.A., U.S.A.
Software (Web Marketplace Saas..) • BioTech • A.I. (& Big Data) • Mobile Apps • Healthcare (& Wellness) • Oncology
Description
Thomas Clozel co-founded Owkin with Gilles Wainrib and serves as Chief Executive Officer. Mr. Clozel attended Weill Medical College of Cornell University and Icahn School of Medicine at Mount Sinai.
Cyriac Roeding
Investing in Software (Web Marketplace Saas..) &b...
How to connect with Angel Investors in the Oncology industry?
In the Oncology industry, angel investors such as Vinod Khosla, Esther Dyson, and Steve Jurvetson are highly active. These investors focus on startups offering innovative solutions in cancer treatment, diagnostics, and research. Vinod Khosla, founder of Khosla Ventures, invests in oncology startups that have the potential to significantly advance cancer care and treatment outcomes. Esther Dyson, an entrepreneur and investor, looks for companies that leverage technology to improve cancer diagnostics and patient care. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups with strong scientific foundations and impactful oncology solutions. To connect with these investors, attend oncology conferences, medical expos, and networking events such as ASCO Annual Meeting, World Cancer Congress, and AACR Annual Meeting. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your oncology solution addresses key challenges, such as improving cancer diagnostics, enhancing treatment efficacy, or advancing research. Highlight any traction you’ve gained, such as partnerships with medical institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as product sales, licensing, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from oncology experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
